Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is advancing its innovative anti-infective therapies, with a focus on orphan indications. The company's lead drug candidate, MAT2203, an orally-administered, encochleated formulation of amphotericin B, has shown promising results in preclinical studies, demonstrating prolonged survival and reduced fungal burden in a neutropenic mouse model of lung infection. These findings suggest the potential for MAT2203 to offer a less toxic and more effective oral treatment for severe fungal infections.
Addressing the Challenge of Fungal Infections
Invasive fungal infections pose a significant threat, particularly to immunocompromised patients. Current treatments, such as intravenous amphotericin B, are often associated with significant toxicity, limiting their use and effectiveness. Matinas BioPharma's proprietary lipid-crystal nano-particle cochleate technology aims to overcome these limitations by enhancing the safety, tolerability, and oral bioavailability of existing drugs.
MAT2203: A Novel Oral Amphotericin B Formulation
MAT2203 is currently in Phase 2 clinical trials, evaluating its efficacy and safety in patients with severe fungal infections. The oral formulation offers a potential advantage over intravenous administration, improving patient convenience and reducing the risk of infusion-related reactions. The encochleated technology protects the amphotericin B from degradation in the gastrointestinal tract, allowing for efficient absorption and delivery to the site of infection.
MAT2501: Targeting Acute Bacterial Infections
In addition to MAT2203, Matinas BioPharma is also developing MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Leveraging Innovative Technology
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients with serious infections.
